Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05717686 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
A Phase 1 study of Chronic Hepatitis B, sponsored by AusperBio Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 9
- Study locations
NCT05717686: Completed Phase 1 study of Chronic Hepatitis B, sponsored by AusperBio Therapeutics.
NCT05717686 is a Phase 1 study of Chronic Hepatitis B that has completed, run by AusperBio Therapeutics. The registered enrollment target is 64 participants, below the 289-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (78% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05717686, a Phase 1 study of Chronic Hepatitis B, has completed, sponsored by AusperBio Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses. In addition, the study will evaluate the initial antiviral efficacy of AHB-137 in CHB patients following a multiple dosing regimen.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AHB-137 injection
Study Locations (9)
Other
- Queen Mary Hospital - Hong Kong
- Chia-Yi Christian Hospital - Chiayi City
Taiwan
- Kaohsiung Medical University Chung-Ho Memorial Hospital - Kaohsiung
- E-DA Hospital - Kaohsiung
California
- Stanford Medicine - Redwood City
Maryland
- University of Maryland Baltimore - Baltimore
New York
- NYU Langone Health - New York
Texas
- American Research Corporation - Houston
Auckland
- New Zealand Clinical Research - Grafton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-01-07 |
| Phase | Phase 1 |
What the finished NCT05717686 record still lists
NCT05717686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 289-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05717686 lists 9 locations in 7 states (Other, Taiwan, California).
Frequently Asked Questions
What is clinical trial NCT05717686 about?
NCT05717686 is a clinical study titled "A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses. In addition, the study will evaluate the initial antiviral efficacy of AHB-137 in...
What is the current status of trial NCT05717686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2023-02-28. Estimated completion is 2025-01-07.
What conditions does trial NCT05717686 study?
This clinical trial studies the following conditions: Chronic Hepatitis B.
What interventions are being tested in trial NCT05717686?
The interventions under investigation include: Placebo (DRUG), AHB-137 injection (DRUG).
Who is sponsoring clinical trial NCT05717686?
This trial is sponsored by AusperBio Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05717686 being conducted?
This trial has 9 study locations across California, Maryland, New York, Texas, Auckland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05717686's enrollment target sits among peer trials
64 11th of 14 higher than 4 of 14 other Chronic Hepatitis B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Hepatitis B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
RECRUITING · Phase 1
-
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
RECRUITING · Phase 2
-
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
RECRUITING · Phase 2
-
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
RECRUITING · Phase 2
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI